TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03331120

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ambulatory mirror image functional re-training through wearing 3D adjustable cervicothoracic Posture Corrective Orthotic(CTPCO)
Description: Ambulatory a mirror image functional re-training This way of functional training will deliver via the use of adjustable cervicothoracic orthosis with the patient walking at approximately 2-3 miles per hour on a standard, motorized treadmill. The brace will reverse the abnormal posture according to the 3D posture analysis data. To facilitate tissue remodeling by reverse posture training, this called mirror image exercise.then the ambulatory exercises by using treadmill will be performed while the patient's mirror image posture will be held by the adjustable orthosis, ambulatory exercises for 20 minutes by using treadmill Based on Harrison et al and Hawes et al., approach, this program will be repeated 3 Times /week for 10 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ambulatory mirror image functional re-training through wearing 3D adjustable cervicothoracic Posture Corrective Orthotic(CTPCO)
Description: Ambulatory a mirror image functional re-training This way of functional training will deliver via the use of adjustable cervicothoracic orthosis with the patient walking at approximately 2-3 miles per hour on a standard, motorized treadmill. The brace will reverse the abnormal posture according to the 3D posture analysis data. To facilitate tissue remodeling by reverse posture training, this called mirror image exercise.then the ambulatory exercises by using treadmill will be performed while the patient's mirror image posture will be held by the adjustable orthosis, ambulatory exercises for 20 minutes by using treadmill Based on Harrison et al and Hawes et al., approach, this program will be repeated 3 Times /week for 10 weeks.
Study: NCT02672046

Intervention type: OTHER
Intervention: Assessment at the Clinic of Sports Injuries
Description: Assessment at the Clinic of Sports Injuries as well as a new algorithm (using patient-reported symptoms will be applied
Study: NCT01204190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gestodene/EE Patch (BAY86-5016)
Description: 0.55 mg ethinyl estradiol (EE) + 2.1 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free interval of 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gestodene/EE Patch (BAY86-5016)
Description: 0.35 mg ethinyl estradiol (EE) + 0.67 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free interval of 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gestodene/EE Patch (BAY86-5016)
Description: 0.275 mg ethiny estradiol (EE) + 1.05 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free interval of 7 days
Study: NCT02683538

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Separable cluster electrode (Octopus®)
Description: Patients undergo RFA under ultrasound guidance, and separable cluster electrodes are used for RFA in monopolar switching mode, using multiple overlapping technique to create larger ablative zones.
Study: NCT03798691

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shingrix
Description: Biological: SHINGRIX~SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 18 years and older.~SHINGRIX is a suspension for injection supplied as a single-dose vial of lyophilized glycoprotein e (ge) antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. A single dose after reconstitution is 0.5 mL.~Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shingrix
Description: Biological: SHINGRIX~SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 18 years and older.~SHINGRIX is a suspension for injection supplied as a single-dose vial of lyophilized glycoprotein e (ge) antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. A single dose after reconstitution is 0.5 mL.~Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later.
Study: NCT00754130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets before every meal (q.a.c) Treatment period is 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets before every meal (q.a.c) Treatment period is 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0941
Description: MK-0941 5 mg tablets q.a.c.; 10 mg tablets q.a.c.; 20 mg tablets q.a.c.; or 40 mg tablets q.a.c. Treatment period is 5 days.
Study: NCT00754130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0941
Description: MK-0941 5 mg tablets q.a.c.; 10 mg tablets q.a.c.; 20 mg tablets q.a.c.; or 40 mg tablets q.a.c. Treatment period is 5 days.
Study: NCT00731276

Intervention type: DRUG
Group type: OTHER
Intervention: irinotecan hydrochloride

Intervention type: OTHER
Group type: OTHER
Intervention: pharmacogenomic studies

Intervention type: OTHER
Group type: OTHER
Intervention: pharmacological study
Study: NCT01107912

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prasugrel
Description: administered orally, daily for 12 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prasugrel
Description: administered orally, daily for 12 days
Study: NCT01734512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus tablet will be taken daily by mouth with water. All patients will be given a dose of 5 mg/m2/dose daily.
Study: NCT01107912

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: Administered orally, daily for 12 days
Study: NCT00904501

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bone marrow harvest
Description: Implantation of placebo

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow harvest
Description: Implantation of bone marrow - mononuclear cells
Study: NCT01870700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lactobacillus reuteri
Description: Lactobacillus reuteri (DSM 17938) was administered in the dose of 108 colony-forming units (CFU) in tablets of a commercially available preparation (Reuflor, Italchimici, Pomezia; BioGaia AB, Stockholm, Sweden), 30 minutes after feeding, twice per day for 4 weeks
Study: NCT01547273

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone graft inside socket only
Description: bone graft inside socket only

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone graft inside and outside socket
Description: bone graft inside and outside socket

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no bone graft
Description: no bone graft
Study: NCT01089985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous serum eyedrops
Description: 3 times a day for the duration of the study
Study: NCT02015468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early mobilization
Description: Early weightbearing and physiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Late mobilization
Description: Late mobilization, none-weightbearing and home exercises
Study: NCT03319901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax is an inhibitor of Bcl-2. Bcl-2 is critical for keeping cancer cells alive.~By inhibiting Bcl-2, venetoclax promotes cancer cell death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Chemotherapy
Description: Standard treatment of chemotherapy is administered
Study: NCT03218631

Intervention type: DRUG
Group type: OTHER
Intervention: Oxandrin
Description: The primary outcome for this study will be measurements of the pharmacokinetics of a single dose of oxandrolone 0.1 mg/kg both in tablet form and in the MCT oil preparation. Blood samples for pharmacokinetics will be drawn at 9 timepoints.~Safety will be assessed by recording adverse events and assessment of hepatic function at baseline and one week following oxandrolone dosing.
Study: NCT00422773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Dose level Infusion time (h) Dose level unit 1 2 3 4 Cetuximab 2.0 mg/m² 500 500 500 500 Irinotecan, before oxaliplatin 1.0 mg/m² 95 125 165 180 Oxaliplatin, with folinic acid 2.0 mg/m² 85 85 85 85 Folinic acid, with folinic acid 2.0 mg/m² 400 400 400 400 5-FU Infusion 46.0 mg/m² 3200 3200 3200 3200
Study: NCT01003548

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMART dynamic system of embryo culture
Description: Embryos will be cultured in a dynamic system of microfluidics.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Static culture
Description: Embryos cultured in 40 microliters microdrops of G-IVF plus series V
Study: NCT00646256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COGPACK training, psychoeducation
Description: Bifocal psychoeducation group program (Munich Psychoses Information Program - PIP) with preceding computerbased cognitive training program (COGPACK)
Study: NCT00612079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertindole
Description: oral 3 x 4mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertindole
Description: oral 3 x 4mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 3 x 4mg Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 3 x 4mg Placebo
Study: NCT02606682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPT200-11
Description: Single doses of NPT200-11capsules, orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPT200-11
Description: Single doses of NPT200-11capsules, orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPT200-11
Description: Single doses of NPT200-11capsules, orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPT200-11
Description: Single doses of NPT200-11capsules, orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPT200-11
Description: Single doses of NPT200-11capsules, orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPT200-11
Description: Single doses of NPT200-11capsules, orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPT200-11
Description: Single doses of NPT200-11capsules, orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single doses of microcrystalline cellulose capsules, orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single doses of microcrystalline cellulose capsules, orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single doses of microcrystalline cellulose capsules, orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single doses of microcrystalline cellulose capsules, orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single doses of microcrystalline cellulose capsules, orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single doses of microcrystalline cellulose capsules, orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single doses of microcrystalline cellulose capsules, orally administered
Study: NCT00612794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide once weekly
Description: subcutaneous injection, once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide once weekly
Description: subcutaneous injection, once weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous injection, once weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous injection, once weekly
Study: NCT00685022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI
Description: 1. Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)~2. Arm #A~3. Xopenex HFA MDI, albuterol HFA MDI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racemic Albuterol followed by levalbuterol HFA MDI
Description: 1. Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)~2. Arm #B~3. albuterol HFA MDI, Xopenex HFA MDI
Study: NCT02243059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadofosveset trisodium (Ablavar™ )

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Study: NCT01831531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 40 mg (BSA ≤ 1.6 m2) or 50 mg (BSA \>1.6 m2) p.o bid d1-28

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
Study: NCT05889026

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal shock wave therapy
Description: Stimulation was given to the brachial muscle, 1000 times, 4Hz, and energy flux density was 0.030mJ/mm2.
Study: NCT01870700

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: a supplementation with placebo was administered in tablets of a commercially available preparation 30 minutes after feeding, twice per day for 4 weeks
Study: NCT05889026

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Botulinum toxin treatment
Description: The toxin dose was established for each patient: it ranged between 80 unit and 300 unit.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin treatment
Description: The toxin dose was established for each patient: it ranged between 80 unit and 300 unit.
Study: NCT04334330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib, Trastuzumab, Pyrotinib and Fulvestrant
Description: ER/PR positive, HER2-positive breast cancer patients with brain metastatic lesions receive palbociclib PO daily on days 1-21, combined with trastuzumab IV every three weeks, pyrotinib PO daily and fulvestrant IM every 4 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Study: NCT03975088

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sub-macular injection of Ranibizumab
Description: In this study, authors describe a new surgical technique for the treatment of refractory non tractional DME. The technique consists of vitrectomy with ILM peeling with subretinal injection of Ranibizumab.
Study: NCT02733601

Intervention type: OTHER
Intervention: NIS (Non Interventional Study) observational study
Description: NIS observational study : Epidemiologic registry
Study: NCT02917928

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: carnosine
Description: Each participant will be given a daily oral dose 2 g of carnosine (4 tablets of 500mg each) for 14 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant will be given a daily oral dose 2 g of placebo (4 tablets of 500mg each) for 14 weeks
Study: NCT01268137

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Deep Brain Stimulation
Description: Surgical electrode implantation in the white matter adjacent to the Cg25 region and implantation of the DBS pulse generating device

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation
Description: Surgical electrode implantation in the white matter adjacent to the Cg25 region and implantation of the DBS pulse generating device
Study: NCT02503566

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography
Description: Optical coherence tomography performed during regular coronary angiography
Study: NCT02523274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Dietary compound commonly found in grapes and red wine. Will be given in 250 mg/day and 1000 mg/day dosages

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Dietary compound commonly found in grapes and red wine. Will be given in 250 mg/day and 1000 mg/day dosages

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vegetable-based cellulose

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Multi-modal exercise regimen, 3 days/week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Multi-modal exercise regimen, 3 days/week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Multi-modal exercise regimen, 3 days/week
Study: NCT01884116

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAID patch + transcutaneous electric nerve stimulation
Description: The patients of the experimental groups will be divided in to three groups according to what they are administered: NSAID patch plus transcutaneous electric nerve stimulation, NSAID patch plus heating pad, and NSAID patch plus topical capsaicin. All the groups will be observed for two weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAID patch + heating pad
Description: The patients of the experimental groups will be divided in to three groups according to what they are administered: NSAID patch plus transcutaneous electric nerve stimulation, NSAID patch plus heating pad, and NSAID patch plus topical capsaicin. All the groups will be observed for two weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAID patch + topical capsaicin
Description: The patients of the experimental groups will be divided in to three groups according to what they are administered: NSAID patch plus transcutaneous electric nerve stimulation, NSAID patch plus heating pad, and NSAID patch plus topical capsaicin. All the groups will be observed for two weeks.
Study: NCT06267677

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High protein liquid formula
Description: liquid and high amount of protein
Study: NCT02316678

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention
Study: NCT02757131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambulation
Description: Patients randomized to the intervention group will be asked to participate in the ambulation protocol outlined by the PT staff 3 times daily under the supervision of the dedicated ambulator PCNA. This protocol will involve four exercise levels (mobilization, standing, walking, stairs) that may be implemented depending on the current physical capacity of the patient. The cohort of patients randomized to ambulator protocol will also receive the usual care by primary nursing.~In an effort to best characterize mobility in these patients, the team will collect Braden Scale Activity data from the electronic health record, and provide each patient a mobility tracking device to directly record daily steps taken while the patient is in the hospital. Daily step counts will be collected on a weekly basis from each device. The Braden Scale is entered by nursing on each patient at least daily and measures current activity level on a 4-point scale.
Study: NCT02952079

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blephex
Description: Lid margin exfoliation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MiboFlo
Description: Lid warming treatment
Study: NCT01903655

Intervention type: OTHER
Group type: OTHER
Intervention: telomere length

Intervention type: OTHER
Group type: OTHER
Intervention: telomere length

Intervention type: OTHER
Group type: OTHER
Intervention: telomere length
Study: NCT02584049

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathy
Description: 3 sessions of osteopathy during 60 minutes each

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham osteopathy
Description: 3 sessions of sham osteopathy during 60 minutes each
Study: NCT01115439

Intervention type: DRUG
Intervention: artesunate plus sulfadoxine-pyrimethamine (AS+SP)
Description: artesunate plus sulfadoxine-pyrimethamine (AS+SP)
Study: NCT04558346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ghrelin (OXE-103)
Description: 40ug/kg twice daily by self-injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 40ug/kg twice daily by self-injection
Study: NCT03223558

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: timing of initiation of cardiac rehabilitation
Description: earlier timing of cardiac rehabilitation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: timing of initiation of cardiac rehabilitation
Description: earlier timing of cardiac rehabilitation
Study: NCT01778465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low salicylate diet
Description: Participants followed a 7 days period under a Low salicylate diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normal Diet
Description: Participants followed a 7 days period under a Normal Diet
Study: NCT02266628

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV-F Vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Study: NCT01527201

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic debridement
Description: Surgeon will debride, or remove, worn out cartilage.
Study: NCT00709384

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prophylactic surgical lesion
Description: A prophylactic peroperative linear lesions connecting the tricuspid annulus with a right atriotomy (surgical dissection plus cryoablation) and the atriotomy with the inferior caval vein (cryoablation alone).
Study: NCT03351023

Intervention type: OTHER
Intervention: no intervention-this was an observational study
Study: NCT00754130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0941
Description: MK-0941 5 mg tablets q.a.c.; 10 mg tablets q.a.c.; 20 mg tablets q.a.c.; or 40 mg tablets q.a.c. Treatment period is 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0941
Description: MK-0941 5 mg tablets q.a.c.; 10 mg tablets q.a.c.; 20 mg tablets q.a.c.; or 40 mg tablets q.a.c. Treatment period is 5 days.